his.sePublikationer
Ändra sökning
Länk till posten
Permanent länk

Direktlänk
BETA
Publikationer (10 of 15) Visa alla publikationer
Bennet, S. M. P., Böhn, L., Störsrud, S., Liljebo, T., Collin, L., Lindfors, P., . . . Simrén, M. (2018). Multivariate modelling of faecal bacterial profiles of patients with IBS predicts responsiveness to a diet low in FODMAPs. Gut, 67(5), 872-881
Öppna denna publikation i ny flik eller fönster >>Multivariate modelling of faecal bacterial profiles of patients with IBS predicts responsiveness to a diet low in FODMAPs
Visa övriga...
2018 (Engelska)Ingår i: Gut, ISSN 0017-5749, E-ISSN 1468-3288, Vol. 67, nr 5, s. 872-881Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Objective The effects of dietary interventions on gut bacteria are ambiguous. Following a previous intervention study, we aimed to determine how differing diets impact gut bacteria and if bacterial profiles predict intervention response. Design Sixty-seven patients with IBS were randomised to traditional IBS (n=34) or low fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs) (n=33) diets for 4 weeks. Food intake was recorded for 4 days during screening and intervention. Faecal samples and IBS Symptom Severity Score (IBS-SSS) reports were collected before (baseline) and after intervention. A faecal microbiota dysbiosis test (GA-map Dysbiosis Test) evaluated bacterial composition. Per protocol analysis was performed on 61 patients from whom microbiome data were available. Results Responders (reduced IBS-SSS by >= 50) to low FODMAP, but not traditional, dietary intervention were discriminated from non-responders before and after intervention based on faecal bacterial profiles. Bacterial abundance tended to be higher in non-responders to a low FODMAP diet compared with responders before and after intervention. A low FODMAP intervention was associated with an increase in Dysbiosis Index (DI) scores in 42% of patients; while decreased DI scores were recorded in 33% of patients following a traditional IBS diet. Non-responders to a low FODMAP diet, but not a traditional IBS diet had higher DI scores than responders at baseline. Finally, while a traditional IBS diet was not associated with significant reduction of investigated bacteria, a low FODMAP diet was associated with reduced Bifidobacterium and Actinobacteria in patients, correlating with lactose consumption. Conclusions A low FODMAP, but not a traditional IBS diet may have significant impact on faecal bacteria. Responsiveness to a low FODMAP diet intervention may be predicted by faecal bacterial profiles.

Ort, förlag, år, upplaga, sidor
BMJ Publishing Group Ltd, 2018
Nationell ämneskategori
Hälsovetenskaper Klinisk medicin
Forskningsämne
Translationell medicin TRIM
Identifikatorer
urn:nbn:se:his:diva-15099 (URN)10.1136/gutjnl-2016-313128 (DOI)000429733600011 ()28416515 (PubMedID)2-s2.0-85042028845 (Scopus ID)
Tillgänglig från: 2018-04-26 Skapad: 2018-04-26 Senast uppdaterad: 2018-08-30Bibliografiskt granskad
Jonefjäll, B., Simrén, M., Lasson, A., Öhman, L. & Strid, H. (2018). Psychological distress, iron deficiency, active disease and female gender are independent risk factors for fatigue in patients with ulcerative colitis. United European Gastroenterology journal, 6(1), 148-158
Öppna denna publikation i ny flik eller fönster >>Psychological distress, iron deficiency, active disease and female gender are independent risk factors for fatigue in patients with ulcerative colitis
Visa övriga...
2018 (Engelska)Ingår i: United European Gastroenterology journal, ISSN 2050-6406, E-ISSN 2050-6414, Vol. 6, nr 1, s. 148-158Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Background: Patients with ulcerative colitis often report fatigue. Objectives: To investigate prevalence of and risk factors for fatigue in patients with ulcerative colitis with active disease and during deep remission. Methods: In this cross-sectional study, disease activity was evaluated with endoscopy and calprotectin, and patients were classified as having active disease (n=133) or being in deep remission (n=155). Blood samples were analysed to assess anaemia, iron deficiency and systemic immune activity. Patients completed questionnaires to assess fatigue, psychological distress, gastrointestinal symptoms and quality of life. Results: The prevalence of high fatigue (general fatigue >= 13, Multidimensional Fatigue Inventory) was 40% in the full study population. Among patients with high fatigue, female gender and iron deficiency were more prevalent, and these patients had more severe disease activity and reported higher levels of anxiety, depression and decreased quality of life compared with patients with no/mild fatigue. A logistic regression analysis identified probable psychiatric disorder (odds ratio (OR) (confidence interval) 6.1 (3.1-12.2)), iron deficiency (OR 2.5 (1.2-5.1)), active disease (OR 2.2 (1.2-3.9)) and female gender (OR 2.1 (1.1-3.7)) as independent risk factors for high fatigue. Similar results were found concerning psychological distress, gender and quality of life, but immune markers did not differ in patients in deep remission with high vs. no/mild fatigue. Conclusions: Probable psychiatric disorder, iron deficiency, active disease and female gender are independent risk factors for high fatigue in patients with ulcerative colitis. Low-grade immune activity does not seem to be the cause of fatigue among patients in deep remission.

Ort, förlag, år, upplaga, sidor
Sage Publications Ltd., 2018
Nyckelord
Ulcerative colitis, inflammatory bowel disease, fatigue, psychiatric disease, iron deficiency, inflammation
Nationell ämneskategori
Klinisk medicin
Forskningsämne
Translationell medicin TRIM
Identifikatorer
urn:nbn:se:his:diva-14708 (URN)10.1177/2050640617703868 (DOI)000423192600018 ()29435325 (PubMedID)2-s2.0-85041138190 (Scopus ID)
Tillgänglig från: 2018-02-01 Skapad: 2018-02-01 Senast uppdaterad: 2019-11-20Bibliografiskt granskad
Klingberg, E., Strid, H., Ståhl, A., Deminger, A., Carlsten, H., Öhman, L. & Forsblad-d'Elia, H. (2017). A longitudinal study of fecal calprotectin and the development of inflammatory bowel disease in ankylosing spondylitis. Arthritis Research & Therapy, 19, Article ID 21.
Öppna denna publikation i ny flik eller fönster >>A longitudinal study of fecal calprotectin and the development of inflammatory bowel disease in ankylosing spondylitis
Visa övriga...
2017 (Engelska)Ingår i: Arthritis Research & Therapy, ISSN 1478-6354, E-ISSN 1478-6362, Vol. 19, artikel-id 21Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Background: Patients with ankylosing spondylitis (AS) are at increased risk of developing inflammatory bowel disease (IBD). We aimed to determine the variation in fecal calprotectin in AS over 5 years in relation to disease activity and medication and also to study the incidence of and predictors for development of IBD. Methods: Fecal calprotectin was assessed at baseline (n = 204) and at 5-year follow-up (n = 164). The patients answered questionnaires and underwent clinical evaluations. At baseline and at 5-year follow-up, ileocolonoscopy was performed in patients with fecal calprotectin = 500 mg/kg and = 200 mg/kg, respectively. The medical records were checked for diagnoses of IBD during the follow-up period. Results: Fecal calprotectin > 50 mg/kg was found in two-thirds of the patients at both study visits. In 80% of the patients, fecal calprotectin changed by < 200 mg/kg between the two measuring points. Baseline fecal calprotectin was positively correlated with Ankylosing Spondylitis Disease Activity Score based on C-reactive protein, Bath Ankylosing Spondylitis Disease Activity Index, Bath Ankylosing Spondylitis Functional Index, C-reactive protein, erythrocyte sedimentation rate, and fecal calprotectin at 5-year follow-up. The use of nonsteroidal anti-inflammatory drugs (NSAIDs) was associated with higher fecal calprotectin, and 3-week cessation of NSAIDs resulted in a drop of a median 116 mg/kg in fecal calprotectin. The use of tumor necrosis factor (TNF) blockers was associated with lower fecal calprotectin at both visits, but the users of TNF receptor fusion proteins had significantly higher fecal calprotectin than users of anti-TNF antibodies at 5-year follow-up. The 5-year incidence of Crohn's disease (CD) was 1.5% and was predicted by high fecal calprotectin. Conclusions: Fecal calprotectin was elevated in a majority of the patients and was associated with disease activity and medication at both visits. CD developed in 1.5% of the patients with AS, and a high fecal calprotectin was the main predictor thereof. The results support a link between inflammation in the gut and the musculoskeletal system in AS. We propose that fecal calprotectin may be a potential biomarker to identify patients with AS at risk of developing IBD.

Ort, förlag, år, upplaga, sidor
BioMed Central, 2017
Nyckelord
Ankylosing spondylitis, Spondylarthritis, Inflammatory bowel disease, Fecal calprotectin, Crohn's disease, Ulcerative colitis, Intestinal inflammation
Nationell ämneskategori
Klinisk medicin
Identifikatorer
urn:nbn:se:his:diva-13497 (URN)10.1186/s13075-017-1223-2 (DOI)000396273500004 ()28148281 (PubMedID)2-s2.0-85011265974 (Scopus ID)
Tillgänglig från: 2017-04-18 Skapad: 2017-04-18 Senast uppdaterad: 2017-11-29Bibliografiskt granskad
Tap, J., Derrien, M., Törnblom, H., Brazeilles, R., Cools-Portier, S., Doré, J., . . . Simrén, M. (2017). Identification of an Intestinal Microbiota Signature Associated With Severity of Irritable Bowel Syndrome. Gastroenterology, 152(1), 111-123.e8
Öppna denna publikation i ny flik eller fönster >>Identification of an Intestinal Microbiota Signature Associated With Severity of Irritable Bowel Syndrome
Visa övriga...
2017 (Engelska)Ingår i: Gastroenterology, ISSN 0016-5085, E-ISSN 1528-0012, Vol. 152, nr 1, s. 111-123.e8Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

BACKGROUND & AIMS: We have limited knowledge about the association between the composition of the intestinal microbiota and clinical features of irritable bowel syndrome (IBS). We collected information on the fecal and mucosa-associated microbiota of patients with IBS and evaluated whether these were associated with symptoms.

METHODS: We collected fecal and mucosal samples from adult patients who met the Rome III criteria for IBS at secondary or tertiary care outpatient clinics in Sweden, as well as from healthy subjects. The exploratory set comprised 149 subjects (110 with IBS and 39 healthy subjects); 232 fecal samples and 59 mucosal biopsy samples were collected and analyzed by 16S ribosomal RNA targeted pyrosequencing. The validation set comprised 46 subjects (29 with IBS and 17 healthy subjects); 46 fecal samples, but no mucosal samples, were collected and analyzed. For each subject, we measured exhaled H2 and CH4, oro-anal transit time, and the severity of psychological and gastrointestinal symptoms. Fecal methanogens were measured by quantitative polymerase chain reaction. Numeric ecology analyses and a machine learning procedure were used to analyze the data.

RESULTS: Fecal microbiota showed covariation with mucosal adherent microbiota. By using classic approaches, we found no differences in fecal microbiota abundance or composition between patients with vs without IBS. A computational statistical technique-like machine learning procedure allowed us to reduce the 16S ribosomal RNA data complexity into a microbial signature for severe IBS, consisting of 90 bacterial operational taxonomic units. We confirmed the robustness of the intestinal microbial signature for severe IBS in the validation set. The signature was able to discriminate between patients with severe symptoms, patients with mild/moderate symptoms, and healthy subjects. By using this intestinal microbiota signature, we found IBS symptom severity to be associated negatively with microbial richness, exhaled CH4, presence of methanogens, and enterotypes enriched with Clostridiales or Prevotella species. This microbiota signature could not be explained by differences in diet or use of medications.

CONCLUSIONS: In analyzing fecal and mucosal microbiota from patients with IBS and healthy individuals, we identified an intestinal microbiota profile that is associated with the severity of IBS symptoms.

TRIAL REGISTRATION NUMBER: NCT01252550.

Ort, förlag, år, upplaga, sidor
Elsevier, 2017
Nationell ämneskategori
Mikrobiologi inom det medicinska området Gastroenterologi
Identifikatorer
urn:nbn:se:his:diva-13208 (URN)10.1053/j.gastro.2016.09.049 (DOI)000390956200034 ()27725146 (PubMedID)2-s2.0-85006287897 (Scopus ID)
Tillgänglig från: 2016-12-07 Skapad: 2016-12-07 Senast uppdaterad: 2019-11-25Bibliografiskt granskad
Magnusson, M. K., Strid, H., Isaksson, S., Simrén, M. & Öhman, L. (2017). The Mucosal Antibacterial Response Profile and Fecal Microbiota Composition Are Linked to the Disease Course in Patients with Newly Diagnosed Ulcerative Colitis. Inflammatory Bowel Diseases, 23(6), 956-966
Öppna denna publikation i ny flik eller fönster >>The Mucosal Antibacterial Response Profile and Fecal Microbiota Composition Are Linked to the Disease Course in Patients with Newly Diagnosed Ulcerative Colitis
Visa övriga...
2017 (Engelska)Ingår i: Inflammatory Bowel Diseases, ISSN 1078-0998, E-ISSN 1536-4844, Vol. 23, nr 6, s. 956-966Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Background: The clinical disease course of ulcerative colitis (UC) varies substantially between individuals and can currently not be reliably predicted. The gut microbiota and the host's immune defense are key players for gut homeostasis and may be linked to disease outcome. The aim of this study was to determine fecal microbiota composition and mucosal antibacterial response profile in untreated patients with newly diagnosed UC and the impact of these factors on disease course. Methods: Stool samples and intestinal biopsies were obtained from therapy-naive newly diagnosed patients with UC. Patients were defined to have mild or moderate/severe disease course assessed by disease activity during the 3 years follow-up. Fecal microbiota was analyzed by the GA-map Dysbiosis test (n = 18), and gene expression in intestinal biopsies was analyzed by RT2 Profiler polymerase chain reaction array (n = 13) and real-time polymerase chain reaction (n = 44). Results: At the time of diagnosis of UC, the fecal microbiota composition discriminated between patients with mild versus moderate/severe disease course. Also, the mucosal antibacterial gene expression response profile differed between patients with mild versus moderate/severe disease course with bactericidal/permeability-increasing protein (BPI) being most important for the discrimination. Mucosal bactericidal/permeability-increasing protein gene expression at diagnosis was higher in patients with mild versus moderate/severe disease course when confirmed in a larger patient cohort (P = 0.0004, n = 44) and was a good predictor for the number of flares during the 3 years follow-up (R-2 = 0.395, P < 0.0001). Conclusions: In patients with newly diagnosed UC, fecal microbiota composition and mucosal antibacterial response profile, especially bactericidal/permeability-increasing protein, are linked to disease course.

Ort, förlag, år, upplaga, sidor
Oxford University Press, 2017
Nationell ämneskategori
Immunologi inom det medicinska området Gastroenterologi
Forskningsämne
Translationell medicin TRIM
Identifikatorer
urn:nbn:se:his:diva-13980 (URN)10.1097/MIB.0000000000001130 (DOI)000405609200016 ()28445247 (PubMedID)2-s2.0-85019683855 (Scopus ID)
Tillgänglig från: 2017-08-11 Skapad: 2017-08-11 Senast uppdaterad: 2019-11-25Bibliografiskt granskad
Sundin, J., Öhman, L. & Simrén, M. (2017). Understanding the Gut Microbiota in Inflammatory and Functional Gastrointestinal Diseases. Psychosomatic Medicine, 79(8), 857-867
Öppna denna publikation i ny flik eller fönster >>Understanding the Gut Microbiota in Inflammatory and Functional Gastrointestinal Diseases
2017 (Engelska)Ingår i: Psychosomatic Medicine, ISSN 0033-3174, E-ISSN 1534-7796, Vol. 79, nr 8, s. 857-867Artikel, forskningsöversikt (Refereegranskat) Published
Abstract [en]

Objective: During the last decade, experimental and observational studies have shown that patients with inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) may have an altered intestinal microbial composition compared with healthy individuals. However, no uniform microbial signature has as yet been detected for either IBD or IBS. This review summarizes the current knowledge of microbial dysbiosis and its potential relationship to the pathophysiology in IBD and IBS. Methods: A selective review was conducted to summarize the current knowledge of gut microbiota in the pathophysiology of IBD and IBS. Results: Experimental and observational studies provide good evidence for intestinal microbial dysbiosis in subgroups of IBD and IBS. Still, no uniform disease pattern has been detected. This is most likely due to the heterogeneous nature of IBD and IBS, in combination with the effects of intrinsic and extrinsic factors. Such intrinsic factors include genetics, the gastrointestinal environment, and the host immune system, whereas extrinsic factors include early life diet, breastfeeding, and method of infant delivery. Conclusions: Recent and ongoing work to define microbial dysbiosis in IBD and IBS shows promise, but future well-designed studies with well-characterized study individuals are needed. It is likely that the microbial dysbiosis in IBD and IBS is dependent on the natural disease course of IBD and symptom pattern in IBS. Therefore, assessment of the entire microbiota along the gastrointestinal tract, in relationship to confounding factors, symptom fluctuations, and other pathophysiological factors, is needed for further understanding of the etiology of these common diseases.

Ort, förlag, år, upplaga, sidor
Lippincott Williams & Wilkins, 2017
Nyckelord
gastrointestinal microbiota, gut-brain axis, inflammatory bowel disease, irritable bowel syndrome, microbial diversity, small intestinal bacterial overgrowth
Nationell ämneskategori
Hälsovetenskaper Klinisk medicin
Forskningsämne
Translationell medicin TRIM
Identifikatorer
urn:nbn:se:his:diva-14297 (URN)10.1097/PSY.0000000000000470 (DOI)000413070100004 ()28422780 (PubMedID)2-s2.0-85017608487 (Scopus ID)
Tillgänglig från: 2017-11-06 Skapad: 2017-11-06 Senast uppdaterad: 2018-02-16Bibliografiskt granskad
Lebrero-Fernandez, C., Wenzel, U. A., Akeus, P., Wang, Y., Strid, H., Simrén, M., . . . Bas-Forsberg, A. (2016). Altered expression of Butyrophilin (BTN) and BTN-like (BTNL) genes in intestinal inflammation and colon cancer. Immunity, Inflammation and Disease, 4(2), 191-200
Öppna denna publikation i ny flik eller fönster >>Altered expression of Butyrophilin (BTN) and BTN-like (BTNL) genes in intestinal inflammation and colon cancer
Visa övriga...
2016 (Engelska)Ingår i: Immunity, Inflammation and Disease, ISSN 2050-4527, Vol. 4, nr 2, s. 191-200Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Several Butyrophilin (BTN) and Btn-like (BTNL) molecules control T lymphocyte responses, and are genetically associated with inflammatory disorders and cancer. In this study, we present a comprehensive expression analysis of human and murine BTN and BTNL genes in conditions associated with intestinal inflammation and cancer. Using real-time PCR, expression of human BTN and BTNL genes was analyzed in samples from patients with ulcerative colitis, irritable bowel syndrome, and colon tumors. Expression of murine Btn and Btnl genes was examined in mouse models of spontaneous colitis (Muc2(-/-)) and intestinal tumorigenesis (Apc(Min/+)). Our analysis indicates a strong association of several of the human genes with ulcerative colitis and colon cancer; while especially BTN1A1, BTN2A2, BTN3A3, and BTNL8 were significantly altered in inflammation, colonic tumors exhibited significantly decreased levels of BTNL2, BTNL3, BTNL8, and BTNL9 as compared to unaffected tissue. Colonic inflammation in Muc2(-/-) mice significantly down-regulated the expression of particularly Btnl1, Btnl4, and Btnl6 mRNA, and intestinal polyps derived from Apc(Min/+) mice displayed altered levels of Btn1a1, Btn2a2, and Btnl1 transcripts. Thus, our data present an association of BTN and BTNL genes with intestinal inflammation and cancer and represent a valuable resource for further studies of this gene family.

Ort, förlag, år, upplaga, sidor
John Wiley & Sons, 2016
Nyckelord
Butyrophilin (Btn)-like (Btnl), colon cancer, immune regulation, intestinal inflammation, irritable bowel syndrome (IBS), ulcerative colitis (UC)
Nationell ämneskategori
Gastroenterologi Immunologi inom det medicinska området
Identifikatorer
urn:nbn:se:his:diva-12992 (URN)10.1002/iid3.105 (DOI)000381570000007 ()
Tillgänglig från: 2016-09-30 Skapad: 2016-09-30 Senast uppdaterad: 2018-01-14Bibliografiskt granskad
Magnusson, M. K., Strid, H., Sapnara, M., Lasson, A., Bajor, A., Ung, K.-A. & Öhman, L. (2016). Anti-TNF Therapy Response in Patients with Ulcerative Colitis Is Associated with Colonic Antimicrobial Peptide Expression and Microbiota Composition. Journal of Crohn's & Colitis, 10(8), 943-952
Öppna denna publikation i ny flik eller fönster >>Anti-TNF Therapy Response in Patients with Ulcerative Colitis Is Associated with Colonic Antimicrobial Peptide Expression and Microbiota Composition
Visa övriga...
2016 (Engelska)Ingår i: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 10, nr 8, s. 943-952Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

BACKGROUND AND AIMS: Anti-tumour necrosis factor [TNF] therapy is used in patients with ulcerative colitis [UC], but not all patients respond to treatment. Antimicrobial peptides [AMPs] and the gut microbiota are essential for gut homeostasis and may be important for treatment outcome. The aim of this study was to determine AMP and microbiota profiles in patients with UC before anti-TNF therapy start and correlate these data to treatment outcome.

METHODS: Serum and biopsies were obtained from UC patients naïve to biological therapy [n = 56] before anti-TNF therapy start [baseline]. Fecal samples were taken at baseline and Weeks 2 and 6. Quantitative proteomic analysis was performed in mucosal biopsies. Expression of AMPs and cytokines was determined in biopsies and serum. Microbiota analysis of fecal samples was performed using GA-map™ Dysbiosis Test and real-time quantitative polymerase chain reaction [rtPCR]. Treatment response was evaluated 12-14 weeks after baseline.

RESULTS: At baseline, proteomic analysis of biopsies showed that treatment responders and non-responders had differential expression of AMPs. Eleven AMP and AMP-related genes were analysed by rtPCR in mucosal biopsies and could together discriminate responders from non-responders at baseline. The most important nominators for response were increased expression of defensin 5 and eosinophilic cationic protein. Microbiota analysis revealed lower dysbiosis indexes and higher abundance of Faecalibacterium prausnitzii in responders compared with non-responders at baseline. Also, abundance of F. prausnitzii increased during induction therapy in responders.

CONCLUSIONS: Anti-TNF therapy responders and non-responders display distinctly separate patterns of mucosal AMP expression and gut microbiota before treatment start. This indicates that intestinal antimicrobial/microbial composition can influence treatment outcome.

Ort, förlag, år, upplaga, sidor
Oxford University Press, 2016
Nyckelord
Anti-TNF, antimicrobial peptides, microbiota
Nationell ämneskategori
Gastroenterologi Mikrobiologi inom det medicinska området
Identifikatorer
urn:nbn:se:his:diva-13002 (URN)10.1093/ecco-jcc/jjw051 (DOI)000383204800010 ()26896085 (PubMedID)2-s2.0-84982858775 (Scopus ID)
Tillgänglig från: 2016-10-05 Skapad: 2016-10-05 Senast uppdaterad: 2019-11-26Bibliografiskt granskad
Gunterberg, V., Simrén, M., Öhman, L., Friberg, P., Jones, M. P., Van Oudenhove, L. & Strid, H. (2016). Autonomic nervous system function predicts the inflammatory response over three years in newly diagnosed ulcerative colitis patients. Neurogastroenterology and Motility, 28(11), 1655-1662
Öppna denna publikation i ny flik eller fönster >>Autonomic nervous system function predicts the inflammatory response over three years in newly diagnosed ulcerative colitis patients
Visa övriga...
2016 (Engelska)Ingår i: Neurogastroenterology and Motility, ISSN 1350-1925, E-ISSN 1365-2982, Vol. 28, nr 11, s. 1655-1662Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

BACKGROUND: The autonomic nervous system (ANS) modulates intestinal inflammation in animal models. Human evidence confirming such modulating influence is limited. We aimed to investigate whether ANS function is associated with inflammatory parameters at disease onset, and whether it predicts the evolution of inflammation in patients with ulcerative colitis (UC).

METHODS: We prospectively monitored 51 patients from onset of UC for 3 years. Upon remission of the onset flare, ANS activity was assessed by heart rate variability analysis and compared with healthy controls. Inflammatory parameters in blood, stool, and colonic biopsies obtained at onset and during follow-up visits were analyzed. Generalized linear models were used to test cross-sectional associations between ANS activity and inflammatory parameters at onset; linear mixed models were used to test whether ANS function at onset predicted the evolution of inflammation over the following 3 years.

KEY RESULTS: Sympathovagal balance was different in UC patients compared to healthy controls, and cross-sectional associated with higher levels of systemic (erythrocyte sedimentation rate [ESR], CRP, TNF-α, IFN-γ) and mucosal inflammation (interleukin-8, IFN-γ) at onset. Conversely, a negative cross-sectional association with parasympathetic activity was found for ESR & TNF-α. Longitudinally, parasympathetic activity at onset predicted systemic (ESR, WBC), but not mucosal inflammation during follow-up.

CONCLUSIONS & INFERENCES: This study further strengthens the association between the ANS system and intestinal inflammation previously found in animal models and recently in patients with inflammatory bowel disease. These results may have important implications for the pathogenesis and treatment of UC.

Nationell ämneskategori
Gastroenterologi
Identifikatorer
urn:nbn:se:his:diva-13204 (URN)10.1111/nmo.12865 (DOI)000387032700006 ()27265090 (PubMedID)2-s2.0-84973366429 (Scopus ID)
Tillgänglig från: 2016-12-07 Skapad: 2016-12-07 Senast uppdaterad: 2017-11-29Bibliografiskt granskad
Ahluwalia, B., Magnusson, M. K., Isaksson, S., Larsson, F. & Öhman, L. (2016). Effects of Aloe barbadensis Mill. extract (AVH200®) on human blood T cell activity in vitro. Journal of Ethnopharmacology, 179, 301-309
Öppna denna publikation i ny flik eller fönster >>Effects of Aloe barbadensis Mill. extract (AVH200®) on human blood T cell activity in vitro
Visa övriga...
2016 (Engelska)Ingår i: Journal of Ethnopharmacology, ISSN 0378-8741, E-ISSN 1872-7573, Vol. 179, s. 301-309Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

ETHNOPHARMACOLOGICAL RELEVANCE: Aloe barbadensis Mill. (Aloe vera) is a widely used medicinal plant well reputed for its diverse therapeutic applications. It has been used for thousands of years in folk medicine to treat various conditions and the Aloe vera gel has been reported to possess anti-inflammatory as well as immunostimulatory and immunomodulatory properties. However, the mode of action is still unclear.

AIM OF THE STUDY: The aim of this study was determine the effects of two well-defined A. barbadensis Mill. extracts AVH200® and AVE200 on human blood T cells in vitro.

MATERIALS AND METHODS: Peripheral blood mononuclear cells (PBMC) from healthy donors were stimulated polyclonally in the presence or absence of AVH200® and AVE200. The T cell phenotype was investigated by flow cytometry, cell proliferation was determined by CFSE dye and thymidine assay, respectively and cytokine secretion was determined by MSD® Multi-Spot Assay system and ELISA.

RESULTS: The presence of AVH200® resulted in a reduced expression of CD25 among CD3(+) T cells and suppression of T cell proliferation in a dose dependent manner. Furthermore, AVH200® reduced the expression of CD28 on CD3(+) T cells. AVH200® also reduced the secretion of IL-2, IFN-γ and IL-17A in PBMC cultures. The AVH200® dose dependent reduction in T cell activation and proliferation recorded in the cell cultures was not due to apoptosis or cell death. Additionally, AVH200® was found to be more effective as compared to AVE200 in reducing T cell activation and proliferation.

CONCLUSION: AVH200® has the potential to reduce the activation, proliferation and cytokine secretion of healthy human blood T cells. Our study suggests that AVH200® has a suppressive effect on human blood T cells in vitro.

Nationell ämneskategori
Immunologi inom det medicinska området
Identifikatorer
urn:nbn:se:his:diva-13207 (URN)10.1016/j.jep.2016.01.003 (DOI)000370884400031 ()26771068 (PubMedID)2-s2.0-84954068207 (Scopus ID)
Tillgänglig från: 2016-12-07 Skapad: 2016-12-07 Senast uppdaterad: 2018-01-13Bibliografiskt granskad
Organisationer
Identifikatorer
ORCID-id: ORCID iD iconorcid.org/0000-0001-8142-2106

Sök vidare i DiVA

Visa alla publikationer